drugset / Trial / NCT04489420
Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM
Non-randomizedSequentialOpen-labelTreatment
Summary
This study will find the maximum safe dose (MSD) or maximum tolerated dose (MTD) of CYNK-001 which are NK cells derived from human placental CD34+ cells and culture-expanded. CYNK-001 cells will be given after lymphodepleting chemotherapy for the systemic cohort (IV) (intravenous). The intratumoral cohort (IT) will not be giving lymphodepletion. The safety of this treatment will be evaluated, and researchers want to learn if NK cells will help in treating recurrent glioblastoma multiforme.
Timeline
- Start
- 2020-10-01
- Primary completion
- 2021-08-10
- Completion
- 2021-08-10
Outcome
Outcome not reported
Stopped (Business): “Business decision.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CYNK001-IT | Cell therapy | 2e+08 cells | Other |
| Subject | CYNK001-IV | Cell therapy | 6e+08 cells | Intravenous |
| Subject | CYNK001-IV | Cell therapy | 1.2e+09 cells | Intravenous |